80mg Clomicalm Tablet - per Tablet

80mg Clomicalm Tablet - per Tablet View larger

£ 4.14 inc. VAT

80mg Clomicalm is used as an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate defecation and urination. VET PRESCRIPTION REQUIRED

More details

61426

Data sheet

Target Animal:Dog (Canine)
Related Condition:As an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques
Pet Prescription Required?:Yes (For UK Orders)
Active Ingredient:Clomipramine hydrochloride
Product Name:80mg Clomicalm Tablet - per Tablet
Pack Size:Sold Individually

More info

This medication may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase this item if you have or are in the process of arranging such a prescription. See information bar for further details.  

Clomicalm is available in divisible flavoured tablets of 3 dosage strengths: Clomicalm 5mg Clomipramine hydrochloride 5.00mg (equivalent to 4.5mg Clomipramine) Clomicalm 20mg Clomipramine hydrochloride 20.00mg (equivalent to 17.9mg Clomipramine) Clomicalm 80mg Clomipramine hydrochloride 80.00mg (equivalent to 71.7mg Clomipramine)

Clomicalm is used as an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.   Dosage and administration Dosage: Clomicalm is administered twice daily at a dose of 1-2mg/kg to give a total daily dose of 2-4mg/kg according to the following table:

Dosage per administration Bodyweight Clomicalm 5mg Clomicalm 20mg Clomicalm 80mg 1.25-2.5kg >2.5-5kg 0.5 tablet 1 tablet     >5-10kg >10-20kg   0.5 tablet 1 tablet   >20-40kg >40-80kg     0.5 tablet 1 tablet Administration: Clomicalm is given orally with or without food. In clinical trials a treatment time of 2-3 months with Clomicalm in combination with behavioural modification techniques was sufficient to control the symptoms of separation-related disorders. Some cases may require longer treatment. In cases showing no improvement after 2 months treatment with Clomicalm should be ceased.

Contra-indications warnings etc
Contra-indications Known hypersensitivity to clomipramine and related tricyclic antidepressants. Do not use in male breeding dogs. Warnings Clomicalm may very rarely cause vomiting changes in appetite lethargy or an elevation in liver enzymes which is reversible when the product is discontinued. Hepato-biliary disease has been reported especially with pre-existing conditions and concurrent administrations of drugs metabolised via the hepatic system. Vomiting may be reduced by co-administration with a small quantity of food. If you notice any serious effects or other effects not mentioned in this leaflet please inform your veterinary surgeon. Special precautions for use Dog: It is recommended that Clomicalm be administered to dogs with cardiovascular dysfunction or epilepsy with caution and only after an assessment of the benefit/risk ratio. Because of its potential anticholinergic properties Clomicalm should also be used with care in dogs with narrow angle glaucoma reduced gastrointestinal motility or urinary retention. Clomicalm should be used under veterinary supervision. The efficacy and safety of Clomicalm has not been established in dogs weighing less than 1.25kg or under 6 months of age. Persons administering the product: In children accidental ingestion should be regarded as serious. There is no specific antidote. In case of accidental ingestion seek medical advice immediately and show the product label to the physician. Overdose in human beings causes anticholinergic effects although central nervous and cardiovascular systems may also be affected. People with known hypersensitivity to clomipramine should administer the product with caution. Use during pregnancy and lactation: The safety of the veterinary medicinal product has not been established in female dogs during pregnancy and lactation. Laboratory animal studies in mice and rats have shown evidence of embryotoxic effects. Interaction with other medicaments: Recommendations on the interaction between Clomicalm and other medicaments are derived from studies in species other than dogs. Clomicalm may increase the effects of the anti-arrhythmic drug quinidine anticholinergic agents (e.g. atropine) other CNS active drugs (e.g. barbiturates benzodiazepines general anaesthetics neuroleptics) sympathomimetics (e.g. adrenaline) and coumarine derivatives. The administration of Clomicalm is not recommended in combination with or within 2 weeks of therapy with monoamine oxidase inhibitors. Simultaneous administration with cimetidine may lead to increased plasma levels of clomipramine. Plasma levels of certain anti-epileptic drugs such as phenytoin and carbamazepine may be increased by coadministration with Clomicalm. Overdose: At overdose with 20mg/kg Clomicalm (5 times the maximum therapeutic dose) bradycardia and arrhythmias (atrioventricular node block and ventricular escape beats) were observed approximately 12 hours after dosing. Overdose with 40mg/kg (20 times the recommended dose) of Clomicalm produced hunched posture tremors flushed abdomen and decreased activity in dogs. Higher doses (500mg/kg i.e. 250 times the recommended dose) produced emesis defecation drooped eyes trembling and quietness. Still higher doses (725mg/kg) produced in addition convulsions and death. Environmental precautions: Any unused veterinary medicinal products or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.   Pharmaceutical precautions Store product in the original container. Keep out of reach and sight of children. Accidental ingestion should be regarded as serious.

Legal category
Clomicalm is a POM-V (Pet Prescription Required)